1166 results about "Therapeutic action" patented technology

A system for treatment of ischemic stroke provides a stroke treatment workflow plan defining series of diagnostic actions and therapeutic actions to be performed at locations within a health care facility identified by beacons detectable by proximity sensors that travel with the patient. A first communications device having wireless communications capabilities receives a signal from a proximity sensor and typically transmits data to a second communications device having a visible timer and configured to receive data from and send data to other wireless communications devices. When the a patient undergoes diagnosis and treatment via the workflow plan, the system tracks the location of the patient within the workflow plan and the time at which the patient is at each location, and records the location of the patient and the time of the location within the workflow plan.

In a subcutaneous implantable cardioverter / defibrillator, cardiac arrhythmias are detected to determine necessary therapeutic action. Cardiac signal information is sensed from far field electrodes implanted in a patient. The sensed cardiac signal information is then amplified and filtered. Parameters such as rate, QRS pulse width, cardiac QRS slew rate, amplitude and stability measures of these parameters from the filtered cardiac signal information are measured, processed and integrated to determine if the cardioverter / defibrillator needs to initiate therapeutic action.

The invention discloses a medicinal balloon catheter and a preparation method thereof. The balloon outside surface of the medicinal balloon catheter is grinded and processed through ultraviolet laser to form the concave-convex non-planar structure on the balloon outside surface. The gaps within the non-planar structure form a drug storage layer. The wavelength of the ultraviolet laser is within the range of 10-400nm. The wall thickness of the medicinal balloon catheter is 15-25 microns. The thickness of the non-planar structure is 8-12 microns. Owning to the concave-convex non-planar structure of the balloon outside surface of the medicinal balloon catheter in the invention, the medicinal adsorption storage capacity is fundamentally improved, namely firstly, the amount of the adsorbed medicine is greatly increased, secondly when medicine adsorbed on balloon passes through blood vessels to reach the site of lesion, the medicine adsorbed on the outer wall of the balloon can be maintained as much as possible and cannot be washed off by blood in the blood vessels and cause loss, and can be effectively transferred to the site of lesion by the balloon so as to have effectively therapeutic action. The medicinal balloon catheter of the invention can be used in not only coronary heart disease, but also various diseases caused by other narrow vessels such as lower extremity arterial stenos is or occlusion caused by diabetes.

In a subcutaneous implantable cardioverter / defibrillator, cardiac arrhythmias are detected to determine necessary therapeutic action. Cardiac signal information is sensed from far field electrodes implanted in a patient. The sensed cardiac signal information is then amplified and filtered. Parameters such as rate, QRS pulse width, cardiac QRS slew rate, amplitude and stability measures of these parameters from the filtered cardiac signal information are measured, processed and integrated to determine if the cardioverter / defibrillator needs to initiate therapeutic action.

The present invention relates to the use of 3-sbustituted phthalide or analogue for preparing the medicine for treating Alzheimer disease or other neurotic disease. The structural formula is shown in the right formula. Filtering is executed through a high-effective living model which integrates gene technique and biological technique. The research shows that most compounds have a certain function that the defective individual recovers learning capacity, wherein a plurality of specific compounds represent better activity. The learning capacity of deflective individual can be recovered for above 85%. Furthermore a stable treating effect can be shown in a plurality of tests.

The invention relates to medicine and veterinary science and discloses a novel method for treating oncological, virulent and somatic diseases whose main target for therapeutic action is embodied in the form of DNA which freely circulates in blood plasma (and other liquid media) and originates from tumoral and mutant cells or cells infected by bacteria, fungi or protozoan and from different microorganisms which reside in the organism thereof. Said invention also relates to novel pharmaceutical compositions and to the use thereof for treating oncological diseases and infectious states provoked by bacteria, fungi and protozoa and non-infectious somatic diseases and states produced by accumulation of somatic mutations in cells of organism. Medicinal and immunological compositions, sorption and physico-chemical engineering and the method for using them in order to treat malignant tumors and other diseases are also disclosed.

The invention relates to the technical field of medical instrument cleaning, and discloses a medical instrument cleaning, disinfecting and drying integrated device. The medical instrument cleaning, disinfecting and drying integrated device is characterized in that an electric push rod is arranged on the top of the outer side of a box, a push rod head of the electric push rod extends into the box to be fixedly connected with a cleaning frame, the bottom of the box is provided with an ultrasonic transducer, a first control valve and a second control valve are both solenoid valves, the top of the box is provided with a dryer and an exhaust vent, and the inner side of the top of the box is provided with a plurality of ultraviolet disinfection lamps; and a power module, a controller and a control panel are further included, and the electric push rod, the first control valve, the second control valve, the ultrasonic transducer, the dryer and the multiple ultraviolet disinfection lamps are connected with the controller through the control panel. By means of the medical instrument cleaning, disinfecting and drying integrated device, the workload of cleaning personnel is greatly saved, safety hazards and health hazards are reduced, the cleaning effect is good, and the therapeutic effect of medical instruments is ensured.

The present disclosure provides a buffered ophthalmic composition for formulation of topically administrable suspensions useful for treating eye disorders by promoting wound healing, delivery of pharmaceutically active agents, and lubricating the eye. In particular the ophthalmic composition includes a buffer solution compatible with application to a mammalian eye, wherein the buffer provides increased mechanism of action of pharmaceutically active agents as well as therapeutic qualities. The ophthalmic composition exhibits dual therapeutic action to alleviate various eye disorders as it concomitantly treats corneal ulcerations and excessive inflammation which results from various eye injuries.

The present invention provides agents and methods for dual modality virtual colonoscopy that gives both anatomical and functional information using hybrid CT / PET scanning. In preferred embodiments, the present invention provides radiolabeled tumor-specific agents and methods for distinguishing benign polyps from malignant tumors. In further embodiments, the present invention provides compositions and methods useful for distinguishing morphological and functional subregions of a selected region of tissue based on relative levels of phospholipid metabolism. Preferred radiolabeled tumor-specific agents are phospholipid ether analogs labeled with a halogen radioisotope. In certain preferred embodiments, the compositions including radiolabeled phospholipid ether analogs have therapeutic actions in addition to functionally identifying malignant tissue.

Providing a comfortable low leak mask assembly for a non-invasive positive pressure air supply device (NIPPV) can improve patient compliance and / or treatment efficacy. The mask system includes: a headgear with straps that are substantially non-stretchable and / or fine-tuned; and / or a mask and / or cushion that includes various components to allow Selected locations on the patient's face improve / customize tightness and / or fit.

The invention discloses a chimeric antigen receptor containing a CD27 intracellular domain, a lentiviral vector and application thereof. The immune receptor tyrosine activation sequence motif of the chimeric antigen receptor containing CD27 intracellular domain contains CD27molecule intracellular signal domain and T cell costimulatory signal molecules. The CD27molecule intracellular signal domain is connected with costimulatory signals related to T cell activation, so that the in-vitro proliferation and apoptosis effect of T cells can be obviously enhanced, and the ratio of young sample Tscm cells (CD45RA+CD62L+) with in vivo therapeutic action and central memory cells (CD45RO+CD62L+) in CAR-T cells is increased; expression of IL-10 factors capable of restraining immunization is reduced, an obvious effect of improving the CAR-T (T cell chimeric antigen receptor) cellular therapy effect is achieved, and a new idea and a new selection are provided for the field of CAR-T cellular therapy.

The invention discloses a process for preparing variable zone genes of high affinity tumor necrosis factor (TNF) resistant monoclonal antibody (F6 mAb) comprising, using recombinated human TNF immune BALB / c mouse to prepare a plurality of mouse Anti-TNF monoclonal antibody, screening high affinity F6 mAb using indirect ELISA method. By cloning the monoclonal antibody light chain and heavy chain variable zone genes, the monoclonal antibody light chain and heavy chain variable zone gene sequence and amino acid sequence can be obtained, and the unicity of the gene sequence and protein sequence can be confirmed.

The present invention provides an application of levo-orinidazole in preparation of medicine for resisting parasitization. The tests show that the levo-orinidazole is superior to dextro-orinidazole and racemic orinidazole in therapeutic action for curing parasitization (special for curing infection of trichomonas vaginalis and cecal amebic infection). Said invention also relates to the conventional dosage forms for clinical application, including oral preparation, venous administration preparation and vaginal medication preparation, etc.

The invention discloses an application of SYK as a hepatic fibrosis / cirrhosis therapeutic target. A test proves that expression of the SYK is increased during a hepatic fibrosis / cirrhosis process, wherein the hepatic fibrosis process is accelerated by promoting activation on hepatic stellate cells. By means of an SYK inhibitor or interference on the expression of the SYK gene, the hepatic fibrosis / cirrhosis process can be retarded effectively, thereby achieving excellent treatment effects.